glp-1 obesity drug study august 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo GLP-1s and Obesity Coverage: Differing

2024;doi:10.1056/NEJMoa2403664

The drug isnt the variable that determines whether you lose muscle

We generated fully human antibodies to specifically block GDF8 (trevogrumab) and ActA (garetosmab), and showed that combining these blocking antibodies results in much greater increases in muscle than either of the antibodies individually, with dual blockade matching the muscle growth induced by broader ActRIIA/B pathway blockade in both mice and non-human primates (NHPs) 28,31

Independent testing, published RTP ranges, and clear dispute processes are signals that a platform takes integrity seriously

Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, representing a distinct but related medication class